人工智能软件Quantib Prostate在多参数磁共振成像检测前列腺癌中的附加价值
单中心研究纳入110例患者,3名不同经验读片者分别在不使用和使用Quantib Prostate人工智能软件支持下阅片,评估其对临床显著前列腺癌检测的诊断效能和读片者间一致性。结果显示该软件未提高有一定经验读片者的检出率,但使无经验读片者(R3)的病灶数、一致性及诊断效能改善。
要点
- 使用Quantib Prostate后R3识别的病灶数由101增至127,读片者间一致性由0.37升至0.41。
- R3的PPV、NPV和AUC分别由0.51升至0.55、0.65升至0.82、0.56升至0.62。
- R1和R2使用该软件后各项指标未见变化。
核心结论
- 使用Quantib Prostate未提高有一定前列腺影像经验读片者对临床显著前列腺癌的检出率,但对无经验读片者显示出性能改善。
研究设计与样本
- 单中心研究(NCT06298305),纳入110例患者,其中102例接受前列腺穿刺活检。
诊断标准与关键数值
- 临床显著前列腺癌检出率为47%;PI-RADS≥3者行靶向加系统穿刺活检,mpMRI阴性但临床高度怀疑前列腺癌者行系统穿刺活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Artificial intelligence (AI) has been proposed to assist radiologists in reporting multiparametric magnetic resonance imaging (mpMRI) of the prostate. We evaluate the diagnostic performance of radiologists with different levels of experience when reporting mpMRI with the support of available AI-based software (Quantib Prostate).
MATERIAL AND METHODS: This is a single-center study (NCT06298305) involving 110 patients. Those with a positive mpMRI (PI-RADS ≥ 3) underwent targeted plus systematic biopsy (TBx plus SBx), while those with a negative mpMRI but a high clinical suspicion of prostate cancer (PCa) underwent SBx. Three readers with different levels of experience, identified as R1, R2, and R3 reviewed all mpMRI. Inter-reader agreement among the three readers with or without the assistance of Quantib Prostate as well as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy for the detection of clinically significant PCa (csPCa) were assessed.
RESULTS: 102 patients underwent prostate biopsy and the csPCa detection rate was 47%. Using Quantib Prostate resulted in an increased number of lesions identified for R3 (101 vs. 127). Inter-reader agreement slightly increased when using Quantib Prostate from 0.37 to 0.41 without vs. with Quantib Prostate, respectively. PPV, NPV and diagnostic accuracy (measured by the area under the curve [AUC]) of R3 improved (0.51 vs. 0.55, 0.65 vs.0.82 and 0.56 vs. 0.62, respectively). Conversely, no changes were observed for R1 and R2.
CONCLUSIONS: Using Quantib Prostate did not enhance the detection rate of csPCa for readers with some experience in prostate imaging. However, for an inexperienced reader, this AI-based software is demonstrated to improve the performance.
TRIAL REGISTRATION: Name of registry: clinicaltrials.gov.
TRIAL REGISTRATION NUMBER: NCT06298305. Date of registration: 2022-09.
引用
- Russo T, Quarta L, Pellegrino F, et al. The added value of artificial intelligence using Quantib Prostate for the detection of prostate cancer at multiparametric magnetic resonance imaging. Radiol Med. 2025. PMID: 40332649. doi:10.1007/s11547-025-02017-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。